$25m milestone payment supports pipeline progress in neurodegenerative disease research
News
AI model Vascul8 offers new hope for pulmonary vascular disease patients
Qureight’s imaging platform validated in peer-reviewed study
Medivir grants global rights to Biossil for remetinostat
Exclusive licensing deal aims to advance promising cancer therapy
Fezolinetant shows real-world promise for menopause symptoms
Preliminary phase 4 data highlights improvements in sleep, work productivity and quality of life
Study reveals survival benefit for CTCL patients treated with mogamulizumab
International registry highlights impact of POTELIGEO in rare lymphoma subtypes
ENA Respiratory secures US$22.4m to advance nasal spray therapy
Funding to support phase 2 trial of INNA-051 aimed at preventing viral respiratory infections
Nxera and Cancer Research UK share promising phase 1 cancer trial results
Early data from novel immunotherapy drug shows tumour response in resistant cancers
GSK and ViiV pledge £6 million to boost community-led health efforts
Global Fund welcomes private sector support ahead of phase 8 replenishment summit
Amivantamab shows promise in head and neck cancer
Subcutaneous therapy delivers 45 percent response rate in difficult-to-treat patients
Saphnelo self-injection recommended for EU approval
CHMP backs once-weekly subcutaneous option for systemic lupus erythematosus
AI tools to be trialled in next phase of MHRA’s Airlock programme
Seven new technologies selected to help transform NHS care and speed up diagnosis
FDA grants fast Track status to Enterome’s EO2463 for follicular lymphoma
Designation supports phase 3 launch in watch-and-wait patients in 2026
NIHR invests £157 million in research partnerships to transform healthcare
Applied Research Collaborations to drive innovation and tackle inequalities across England
Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
AbbVie unveils new data on solid tumour therapies
Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers
